{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:18:53Z","timestamp":1792613933452,"version":"4.5.0"},"reference-count":279,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T00:00:00Z","timestamp":1761436800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Medical University of Silesia, Katowice, Poland","award":["BNW-1-091\/K\/4\/I"],"award-info":[{"award-number":["BNW-1-091\/K\/4\/I"]}]},{"name":"Medical University of Silesia, Katowice, Poland","award":["BNW-1-096\/N\/5\/I"],"award-info":[{"award-number":["BNW-1-096\/N\/5\/I"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Despite continuous advances in the development of methodologies for the diagnosis and therapeutic treatment of cancer, the disease remains a primary cause of mortality worldwide. A comprehensive understanding of the molecular mechanisms underlying cancer could ultimately lead to increasingly effective therapeutic interventions. One approach that could be adopted is to formulate methodologies that impede cell signalling and\/or the expression of genes pivotal to carcinogenesis. A notable example of this strategy is the focus on the estrogen receptor, a key player in the development of various types of cancer. The deregulation of this receptor, and the subsequent impact on cell function, is a critical factor in the progression of these diseases. This renders it a significant therapeutic target. Furthermore, the microenvironment has been demonstrated to exert a significant influence on the development of cancers. A mounting body of evidence indicates that the abnormal physical properties of the tumour microenvironment can induce widespread changes, leading to the selection of characteristic tumour cell abilities and subsequent clonal proliferation. This process is accompanied by an increased capacity for invasive growth and, notably, the induction of multidrug resistance. The present article focuses on presenting the structure and role of the estrogen receptor in selected hormone-dependent cancers, its involvement in the formation of the tumor microenvironment, currently used therapeutic methods in the treatment of these cancers, and the challenges associated with them. Each new discovery in the field of cancer biology offers the prospect of developing new potential treatments, including targeted therapies aimed at improving the survival of patients suffering from hormone-dependent malignant tumours. Although the role of the estrogen receptor in their development is well established, further research is required to develop a detailed understanding of how its specific isoforms act in different types of cancer.<\/jats:p>","DOI":"10.3390\/biomedicines13112620","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T07:31:58Z","timestamp":1761550318000},"page":"2620","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Estrogen Receptors as Key Factors in Carcinogenesis"],"prefix":"10.3390","volume":"13","author":[{"given":"Oliwia","family":"Gruszka","sequence":"first","affiliation":[{"name":"Department of Biotechnology and Genetic Engineering, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, 40-055 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7746-7333","authenticated-orcid":false,"given":"Magdalena","family":"Jurzak","sequence":"additional","affiliation":[{"name":"Department of Biotechnology and Genetic Engineering, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, 40-055 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3003-5437","authenticated-orcid":false,"given":"Ilona Anna","family":"Bednarek","sequence":"additional","affiliation":[{"name":"Department of Biotechnology and Genetic Engineering, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, 40-055 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,26]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2025.0473","article-title":"National Cancer System Characteristics and Global Pan-Cancer Outcomes","volume":"11","author":"Dee","year":"2025","journal-title":"JAMA Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Jafari, H., Hussain, S., and Campbell, M.J. (2022). Nuclear Receptor Coregulators in Hormone-Dependent Cancers. Cancers, 14.","DOI":"10.3390\/cancers14102402"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Hamid, A.A., Issa, M.B., and Nizar, N.N.A. (2018). Hormones. Preparation and Processing of Religious and Cultural Foods, Elsevier.","DOI":"10.1016\/B978-0-08-101892-7.00013-4"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Montaruli, A., Castelli, L., Mul\u00e8, A., Scurati, R., Esposito, F., Galasso, L., and Roveda, E. (2021). Biological Rhythm and Chronotype: New Perspectives in Health. Biomolecules, 11.","DOI":"10.3390\/biom11040487"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Liu, Y.C., Yeh, C.T., and Lin, K.H. (2019). Molecular Functions of Thyroid Hormone Signaling in Regulation of Cancer Progression and Anti-Apoptosis. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20204986"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.cca.2022.04.995","article-title":"Sex steroid hormones in urinary exosomes as biomarkers for the prediction of prostate cancer","volume":"531","author":"Chu","year":"2022","journal-title":"Clin. Chim. Acta"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.tem.2020.07.002","article-title":"The Sex Bias of Cancer","volume":"31","author":"Costa","year":"2020","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Boye, A., Osei, S., and Brah, A. (2024). Therapeutic prospects of sex hormone receptor signaling in hormone-responsive cancers. Biomed. Pharmacother., 180.","DOI":"10.1016\/j.biopha.2024.117473"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Pakdel, F. (2023). The Role of Estrogen Receptors in Health and Disease. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241411354"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Pakdel, F. (2018). Molecular Pathways of Estrogen Receptor Action. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19092591"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"930227","DOI":"10.3389\/fendo.2022.930227","article-title":"ER\u03b1 and ER\u03b2 Homodimers in the Same Cellular Context Regulate Distinct Transcriptomes and Functions","volume":"13","author":"Song","year":"2022","journal-title":"Front. Endocrinol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e155476","DOI":"10.1172\/JCI155476","article-title":"The role of estrogen receptor signaling in suppressing the immune response to cancer","volume":"131","author":"Rae","year":"2021","journal-title":"J. Clin. Investig."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"839005","DOI":"10.3389\/fendo.2022.839005","article-title":"Role of estrogen receptors in health and disease","volume":"13","author":"Chen","year":"2022","journal-title":"Front. Endocrinol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Langdon, S.P., Herrington, C.S., Hollis, R.L., and Gourley, C. (2020). Estrogen Signaling and Its Potential as a Target for Therapy in Ovarian Cancer. Cancers, 12.","DOI":"10.3390\/cancers12061647"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Arneth, B. (2019). Tumor Microenvironment. Medicina, 56.","DOI":"10.3390\/medicina56010015"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Kozie\u0142, M.J., and Piastowska-Ciesielska, A.W. (2023). Estrogens, Estrogen Receptors and Tumor Microenvironment in Ovarian Cancer. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241914673"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/bs.apcsb.2019.01.001","article-title":"Estrogen receptor signaling mechanisms","volume":"116","author":"Fuentes","year":"2019","journal-title":"Adv. Protein Chem. Struct. Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2017.12.012","article-title":"Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment","volume":"186","author":"Patel","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13058-021-01462-3","article-title":"ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer","volume":"23","author":"Brett","year":"2021","journal-title":"Breast Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","article-title":"A view on drug resistance in cancer","volume":"575","author":"Vasan","year":"2019","journal-title":"Nature"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Neupane, N., Bawek, S., Gurusinghe, S., Ghaffary, E.M., Mirmosayyeb, O., Thapa, S., Falkson, C., O\u2019Regan, R., and Dhakal, A. (2024). Oral SERD, a Novel Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer. Cancers, 16.","DOI":"10.3390\/cancers16030619"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4299","DOI":"10.1158\/1078-0432.CCR-24-1073","article-title":"Elacestrant in ER+, HER2- Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4\/6 Inhibitor and in Clinical Subgroups","volume":"30","author":"Bardia","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"916804","DOI":"10.3389\/fonc.2022.916804","article-title":"The Isoforms of Estrogen Receptor Alpha and Beta in Thyroid Cancer","volume":"12","author":"Gong","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Belluti, S., Imbriano, C., and Casarini, L. (2023). Nuclear Estrogen Receptors in Prostate Cancer: From Genes to Function. Cancers, 15.","DOI":"10.3390\/cancers15184653"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1042\/EBC20200167","article-title":"The physiological role of estrogen receptor functional domains","volume":"65","author":"Arao","year":"2021","journal-title":"Essays Biochem."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Bano, A., Stevens, J.H., Modi, P.S., Gustafsson, J.\u00c5., and Strom, A.M. (2023). Estrogen Receptor \u03b24 Regulates Chemotherapy Resistance and Induces Cancer Stem Cells in Triple Negative Breast Cancer. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24065867"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Tirado-Garibay, A.C., Falc\u00f3n-Ruiz, E.A., Ochoa-Zarzosa, A., and L\u00f3pez-Meza, J.E. (2023). GPER: An Estrogen Receptor Key in Metastasis and Tumoral Microenvironments. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241914993"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jsbmb.2017.03.021","article-title":"Twenty years of the G protein-coupled estrogen receptor GPER: Historical and personal perspectives","volume":"176","author":"Barton","year":"2018","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3389\/fendo.2020.00545","article-title":"GPER as a Receptor for Endocrine-Disrupting Chemicals (EDCs)","volume":"11","author":"Vanacker","year":"2020","journal-title":"Front. Endocrinol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1053\/j.gastro.2021.11.037","article-title":"The Origin and Contribution of Cancer-Associated Fibroblasts in Colorectal Carcinogenesis","volume":"162","author":"Kobayashi","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13058-023-01684-7","article-title":"Enhancement of PD-L1-attenuated CAR-T cell function through breast cancer-associated fibroblasts-derived IL-6 signaling via STAT3\/AKT pathways","volume":"25","author":"Chuangchot","year":"2023","journal-title":"Breast Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Shin, E., and Koo, J.S. (2022). Cell Component and Function of Tumor Microenvironment in Thyroid Cancer. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232012578"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/cac2.12291","article-title":"Cancer-associated fibroblasts in breast cancer: Challenges and opportunities","volume":"42","author":"Hu","year":"2022","journal-title":"Cancer Commun."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13058-024-01887-6","article-title":"Single-cell transcriptional atlas of tumor-associated macrophages in breast cancer","volume":"26","author":"Zhang","year":"2024","journal-title":"Breast Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1038\/s41598-019-39553-z","article-title":"Cancer associated fibroblasts sculpt tumour microenvironment by recruiting monocytes and inducing immunosuppressive PD-1+ TAMs","volume":"9","author":"Gunaydin","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1186\/s12967-025-06643-8","article-title":"Unraveling the role of M2 TAMs in ovarian cancer dynamics: A systematic review","volume":"23","author":"Wang","year":"2025","journal-title":"J. Transl. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1084\/jem.20180765","article-title":"Heterotypic CAF-tumor spheroids promote early peritoneal metastatis of ovarian cancer","volume":"216","author":"Gao","year":"2019","journal-title":"J. Exp. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1007\/s00405-018-5061-x","article-title":"Clinicopathological significance of cancer-associated fibroblasts in papillary thyroid carcinoma: A predictive marker of cervical lymph node metastasis","volume":"275","author":"Cho","year":"2018","journal-title":"Eur. Arch. Otorhinolaryngol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.62347\/BHFA4606","article-title":"Anaplastic thyroid cancer cell-secreted TGF\u03b21 plays a key role in inducing macrophage polarization of human monocytes","volume":"14","author":"Jaroszewski","year":"2024","journal-title":"Am. J. Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s11033-025-10573-5","article-title":"Autophagy mediated immune response regulation and drug resistance in cancer","volume":"52","author":"Bandyopadhyay","year":"2025","journal-title":"Mol. Biol. Rep."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"938","DOI":"10.4149\/neo_2021_201226N1404","article-title":"Tumor-associated macrophages increase COX-2 expression promoting endocrine resistance in breast cancer via the PI3K\/Akt\/mTOR pathway","volume":"68","author":"Qin","year":"2021","journal-title":"Neoplasma"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/cas.14230","article-title":"Tumor-associated macrophages secrete CC-chemokine ligand 2 and induce tamoxifen resistance by activating PI3K\/Akt\/mTOR in breast cancer","volume":"111","author":"Li","year":"2020","journal-title":"Cancer Sci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/hed.27695","article-title":"Tumor microenvironment in thyroid cancer: Immune cells, patterns, and novel treatments","volume":"46","author":"Febrero","year":"2024","journal-title":"Head Neck."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"835","DOI":"10.25122\/jml-2022-0085","article-title":"Investigating the molecular mechanisms of Tamoxifen on the EMT pathway among patients with breast cancer","volume":"15","author":"Mirzaei","year":"2022","journal-title":"J. Med. Life"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Hassn Mesrati, M., Syafruddin, S.E., Mohtar, M.A., and Syahir, A. (2021). CD44: A Multifunctional Mediator of Cancer Progression. Biomolecules, 11.","DOI":"10.3390\/biom11121850"},{"key":"ref_47","first-page":"e126","article-title":"Targeting Hyaluronic Acid and Peritoneal Dissemination in Colorectal Cancer","volume":"21","author":"Soliman","year":"2022","journal-title":"Clin. Color. Cancer."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.ccell.2021.03.012","article-title":"Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations","volume":"39","author":"Affo","year":"2021","journal-title":"Cancer Cell"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Kellett-Clarke, H., Stegmann, M., Barclay, A.N., and Metcalfe, C. (2015). CD44 Binding to Hyaluronic Acid Is Redox Regulated by a Labile Disulfide Bond in the Hyaluronic Acid Binding Site. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0138137"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.mce.2018.05.008","article-title":"Increase in hyaluronic acid degradation decreases the expression of estrogen receptor alpha in MCF7 breast cancer cell line","volume":"476","author":"Hanoux","year":"2018","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Trnkova, L., Buocikova, V., Mego, M., Cumova, A., Burikova, M., Bohac, M., Miklikova, S., Cihova, M., and Smolkova, B. (2024). Epigenetic deregulation in breast cancer microenvironment: Implications for tumor progression and therapeutic strategies. Biomed. Pharmacother., 174.","DOI":"10.1016\/j.biopha.2024.116559"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.2147\/IJGM.S463649","article-title":"Unveiling Collagen\u2019s Role in Breast Cancer: Insights into Expression Patterns, Functions and Clinical Implications","volume":"17","author":"Li","year":"2024","journal-title":"Int. J. Gen. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.18632\/oncotarget.13716","article-title":"siRNA-mediated suppression of collagen type iv alpha 2 (COL4A2) mRNA inhibits triple-negative breast cancer cell proliferation and migration","volume":"8","author":"JingSong","year":"2017","journal-title":"Oncotarget"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1007\/s40279-022-01733-9","article-title":"Mechanisms of Estrogen Influence on Skeletal Muscle: Mass, Regeneration, and Mitochondrial Function","volume":"52","author":"Pellegrino","year":"2022","journal-title":"Sports Med."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Inoue, C., Miki, Y., and Suzuki, T. (2023). New Perspectives on Sex Steroid Hormones Signaling in Cancer-Associated Fibroblasts of Non-Small Cell Lung Cancer. Cancers, 15.","DOI":"10.3390\/cancers15143620"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/s41388-024-02973-x","article-title":"Cancer-associated fibroblasts rewire the estrogen receptor response in luminal breast cancer, enabling estrogen independence","volume":"43","author":"Reid","year":"2024","journal-title":"Oncogene"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/s41401-020-00500-8","article-title":"Emerging roles of class I PI3K inhibitors in modulating tumor microenvironment and immunity","volume":"41","author":"Sun","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/hep.31410","article-title":"The Tumor Microenvironment in Cholangiocarcinoma Progression","volume":"73","author":"Fabris","year":"2021","journal-title":"Hepatology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1295257","DOI":"10.3389\/fimmu.2023.1295257","article-title":"Tumor-associated macrophages: An effective player of the tumor microenvironment","volume":"14","author":"Basak","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/j.cell.2024.02.009","article-title":"Embracing cancer complexity: Hallmarks of systemic disease","volume":"187","author":"Swanton","year":"2024","journal-title":"Cell"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/s41568-024-00714-6","article-title":"Towards targeting the breast cancer immune microenvironment","volume":"24","author":"Harris","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e22597","DOI":"10.1096\/fj.202200164RR","article-title":"Estrogen-responsive cancer-associated fibroblasts promote invasive property of gastric cancer in a paracrine manner via CD147 production","volume":"36","author":"Bae","year":"2022","journal-title":"FASEB J."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e516","DOI":"10.1002\/ctm2.516","article-title":"Estrogen receptor variant ER\u03b146 and insulin receptor drive in primary breast cancer cells growth effects and interleukin 11 induction prompting the motility of cancer-associated fibroblasts","volume":"11","author":"Cirillo","year":"2021","journal-title":"Clin. Transl. Med."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Nagel, A., Popeda, M., Muchlinska, A., Sadej, R., Szade, J., Zielinski, J., Skokowski, J., Niemira, M., Kretowski, A., and Markiewicz, A. (2022). ER\u03b136-High Cancer-Associated Fibroblasts as an Unfavorable Factor in Triple-Negative Breast Cancer. Cancers, 14.","DOI":"10.3390\/cancers14082005"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e70131","DOI":"10.1002\/ctm2.70131","article-title":"Microenvironmental G protein-coupled estrogen receptor-mediated glutamine metabolic coupling between cancer-associated fibroblasts and triple-negative breast cancer cells governs tumour progression","volume":"14","author":"He","year":"2024","journal-title":"Clin. Transl. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"844142","DOI":"10.3389\/fimmu.2022.844142","article-title":"Immunotherapy: Reshape the Tumor Immune Microenvironment","volume":"13","author":"Lv","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"888713","DOI":"10.3389\/fimmu.2022.888713","article-title":"Shaping Polarization of Tumor-Associated Macrophages in Cancer Immunotherapy","volume":"13","author":"Gao","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Castellaro, A.M., Rodriguez-Baili, M.C., Di Tada, C.E., and Gil, G.A. (2019). Tumor-Associated Macrophages Induce Endocrine Therapy Resistance in ER+ Breast Cancer Cells. Cancers, 11.","DOI":"10.3390\/cancers11020189"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"649815","DOI":"10.3389\/fcimb.2021.649815","article-title":"The Immune Microenvironment in Human Papilloma Virus-Induced Cervical Lesions-Evidence for Estrogen as an Immunomodulator","volume":"11","author":"Jayshree","year":"2021","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Sharpe, M.A., Baskin, D.S., Jenson, A.V., and Baskin, A.M. (2021). Hijacking Sexual Immuno-Privilege in GBM-An Immuno-Evasion Strategy. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222010983"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13058-023-01671-y","article-title":"Estrogen receptor blockade and radiation therapy cooperate to enhance the response of immunologically cold ER+\u2009breast cancer to immunotherapy","volume":"25","author":"Bates","year":"2023","journal-title":"Breast Cancer Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-023-00846-y","article-title":"Myeloid-derived suppressor cells in cancer and cancer therapy","volume":"21","author":"Lasser","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"687","DOI":"10.3389\/fimmu.2020.00687","article-title":"Myeloid-Derived Suppressor Cell-Derived Arginase-1 Oppositely Modulates IL-17A and IL-17F Through the ESR\/STAT3 Pathway During Colitis in Mice","volume":"11","author":"Ma","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.18632\/oncotarget.26711","article-title":"Estrogen stimulates female cancer progression by inducing myeloid-derived suppressive cells: Investigations on pregnant and non-pregnant experimental models","volume":"10","author":"Kozasa","year":"2019","journal-title":"Oncotarget"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1111\/febs.17270","article-title":"Estrogen receptors and extracellular matrix: The critical interplay in cancer development and progression","volume":"292","author":"Mangani","year":"2025","journal-title":"FEBS J."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12964-019-0409-4","article-title":"Novel interactions between ER\u03b1-36 and STAT3 mediate breast cancer cell migration","volume":"17","author":"Xiang","year":"2019","journal-title":"Cell Commun. Signal."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.semcancer.2019.07.006","article-title":"Estrogen receptor-mediated targeting of the extracellular matrix network in cancer","volume":"62","author":"Piperigkou","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13058-017-0801-1","article-title":"Elevated collagen-I augments tumor progressive signals, intravasation and metastasis of prolactin-induced estrogen receptor alpha positive mammary tumor cells","volume":"19","author":"Barcus","year":"2017","journal-title":"Breast Cancer Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/ijc.35278","article-title":"The GLOBOCAN 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwide","volume":"156","author":"Filho","year":"2025","journal-title":"Int. J. Cancer"},{"key":"ref_80","first-page":"1201","article-title":"Circulating estrogens and postmenopausal ovarian and endometrial cancer risk among current hormone users in the Women\u2019s Health Initiative Observational Study","volume":"30","author":"Trabert","year":"2019","journal-title":"Cancer Causes Control"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3892\/or.2021.8174","article-title":"Hormone therapy for ovarian cancer: Emphasis on mechanisms and applications (Review)","volume":"46","author":"Li","year":"2021","journal-title":"Oncol. Rep."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Smolarz, B., Biernacka, K., \u0141ukasiewicz, H., Samulak, D., Piekarska, E., Romanowicz, H., and Makowska, M. (2025). Ovarian Cancer-Epidemiology, Classification, Pathogenesis, Treatment, and Estrogen Receptors\u2019 Molecular Backgrounds. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26104611"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Salvati, A., Gigantino, V., Nassa, G., Giurato, G., Alexandrova, E., Rizzo, F., Tarallo, R., and Weisz, A. (2019). The Histone Methyltransferase DOT1L Is a Functional Component of Estrogen Receptor Alpha Signaling in Ovarian Cancer Cells. Cancers, 11.","DOI":"10.3390\/cancers11111720"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1080\/15384047.2016.1235656","article-title":"Activation of estrogen receptor \u03b1 by estradiol and cisplatin induces platinum-resistance in ovarian cancer cells","volume":"18","author":"Matsumura","year":"2017","journal-title":"Cancer Biol. Ther."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1134\/S1607672918050058","article-title":"Estrogen Receptors alpha and beta in Ovarian Cancer: Expression Level and Prognosis","volume":"482","author":"Bogush","year":"2018","journal-title":"Dokl. Biochem. Biophys."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Chauvin, S., Cohen-Tannoudji, J., and Guigon, C.J. (2022). Estradiol Signaling at the Heart of Folliculogenesis: Its Potential Deregulation in Human Ovarian Pathologies. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23010512"},{"key":"ref_87","first-page":"012005","article-title":"Relationship of estrogen beta (ER\u03b2) receptor genes polymorphism with epithelial ovarian cancer","volume":"1246","author":"Andreinie","year":"2019","journal-title":"J. Phys."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1383939","DOI":"10.3389\/fonc.2024.1383939","article-title":"Nuclear receptors in ovarian cancer: Changing paradigms in cancer therapeutics","volume":"14","author":"Sajeev","year":"2024","journal-title":"Front. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"8719","DOI":"10.1007\/s00432-023-04708-z","article-title":"Nuclear receptor co-repressor NCOR2 and its relation to GPER with prognostic impact in ovarian cancer","volume":"149","author":"Reichenbach","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"209","DOI":"10.5487\/TR.2019.35.3.209","article-title":"Role of G Protein-Coupled Estrogen Receptor in Cancer Progression","volume":"35","author":"Jung","year":"2019","journal-title":"Toxicol. Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1007\/s00432-020-03333-4","article-title":"G protein-coupled estrogen receptor 1 (GPER-1) and agonist G-1 inhibit growth of ovarian cancer cells by activation of anti-tumoral transcriptome responses: Impact of GPER-1 mRNA on survival","volume":"146","author":"Skrzypczak","year":"2020","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Han, N., Heublein, S., Jeschke, U., Kuhn, C., Hester, A., Czogalla, B., Mahner, S., Rottmann, M., Mayr, D., and Schmoeckel, E. (2021). The G-Protein-Coupled Estrogen Receptor (GPER) Regulates Trimethylation of Histone H3 at Lysine 4 and Represses Migration and Proliferation of Ovarian Cancer Cells In Vitro. Cells, 10.","DOI":"10.3390\/cells10030619"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"To\u00e0n, N.M. (2024). Novel Molecular Classification of Breast Cancer with PET Imaging. Medicina, 60.","DOI":"10.3390\/medicina60122099"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"46","DOI":"10.5858\/arpa.2022-0070-RA","article-title":"Molecular Classification of Breast Cancer: Relevance and Challenges","volume":"147","author":"Zhang","year":"2023","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"bqad020","DOI":"10.1210\/endocr\/bqad020","article-title":"Progesterone Receptor Gene Polymorphisms and Breast Cancer Risk","volume":"164","author":"Vang","year":"2023","journal-title":"Endocrinology"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11912-016-0551-8","article-title":"Age-related Disparity: Breast Cancer in the Elderly","volume":"18","author":"Gosain","year":"2016","journal-title":"Curr. Oncol. Rep."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1056\/NEJMra1707939","article-title":"Breast Cancer in Men","volume":"378","author":"Giordano","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00428-021-03190-7","article-title":"Male breast cancer: An update","volume":"480","author":"Fox","year":"2022","journal-title":"Virchows Arch."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1093\/jbi\/wbac095","article-title":"Breast Cancer Screening in Men","volume":"5","author":"Gao","year":"2023","journal-title":"J. Breast Imaging"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/S0140-6736(20)32381-3","article-title":"Breast cancer","volume":"397","author":"Loibl","year":"2021","journal-title":"Lancet"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Mayrovitz, H.N. (2022). Subtypes of Breast Cancer. Breast Cancer, Exon Publications.","DOI":"10.36255\/exon-publications-breast-cancer"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"690","DOI":"10.2174\/1389450119666181015114041","article-title":"Estrogen Receptor Alpha and its Ubiquitination in Breast Cancer Cells","volume":"20","year":"2019","journal-title":"Curr. Drug Targets"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1200\/JCO.2016.67.1487","article-title":"Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline","volume":"34","author":"Rugo","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Porras, L., Ismail, H., and Mader, S. (2021). Positive Regulation of Estrogen Receptor Alpha in Breast Tumorigenesis. Cells, 10.","DOI":"10.3390\/cells10112966"},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Clusan, L., Ferri\u00e8re, F., Flouriot, G., and Pakdel, F. (2023). A Basic Review on Estrogen Receptor Signaling Pathways in Breast Cancer. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24076834"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3389\/fendo.2020.00506","article-title":"A Role for Estrogen Receptor alpha36 in Cancer Progression","volume":"11","author":"Pagano","year":"2020","journal-title":"Front. Endocrinol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1194\/jlr.M085191","article-title":"Sphingosine kinase 1 activation by estrogen receptor \u03b136 contributes to tamoxifen resistance in breast cancer","volume":"59","author":"Maczis","year":"2018","journal-title":"J. Lipid Res."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Clusan, L., Le Goff, P., Flouriot, G., and Pakdel, F. (2021). A Closer Look at Estrogen Receptor Mutations in Breast Cancer and Their Implications for Estrogen and Antiestrogen Responses. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22020756"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"e2104162118","DOI":"10.1073\/pnas.2104162118","article-title":"Drivers and suppressors of triple-negative breast cancer","volume":"118","author":"Wu","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4048\/jbc.2022.25.e9","article-title":"Estrogen Receptor \u03b2 Expression and Its Clinical Implication in Breast Cancers: Favorable or Unfavorable?","volume":"25","author":"Choi","year":"2022","journal-title":"J. Breast Cancer"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41523-022-00472-4","article-title":"High GPER expression in triple-negative breast cancer is linked to pro-metastatic pathways and predicts poor patient outcomes","volume":"8","author":"Xu","year":"2022","journal-title":"npj Breast Cancer"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41420-023-01654-0","article-title":"GPER deletion triggers inhibitory effects in triple negative breast cancer (TNBC) cells through the JNK\/c-Jun\/p53\/Noxa transduction pathway","volume":"9","author":"Cirillo","year":"2023","journal-title":"Cell Death Discov."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.molonc.2016.01.002","article-title":"Activation of GPER suppresses epithelial mesenchymal transition of triple negative breast cancer cells via NF-\u03baB signals","volume":"10","author":"Chen","year":"2016","journal-title":"Mol. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Kampa, M., Lappano, R., Grande, F., Rizzuti, B., Maggiolini, M., Castanas, E., and Jacquot, Y. (2023). Promising Perspectives of the Antiproliferative GPER Inverse Agonist ER\u03b117p in Breast Cancer. Cells, 12.","DOI":"10.3390\/cells12040653"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13046-020-01667-y","article-title":"The IL1\u03b2-IL1R signaling is involved in the stimulatory effects triggered by hypoxia in breast cancer cells and cancer-associated fibroblasts (CAFs)","volume":"39","author":"Lappano","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/s12935-019-0935-6","article-title":"Interaction between 17\u03b2-estradiol, prolactin and human papillomavirus induce E6\/E7 transcript and modulate the expression and localization of hormonal receptors","volume":"19","year":"2019","journal-title":"Cancer Cell Int."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"25946","DOI":"10.18632\/oncotarget.25408","article-title":"Low expression of G protein-coupled oestrogen receptor 1 (GPER) is associated with adverse survival of breast cancer patients","volume":"9","author":"Martin","year":"2018","journal-title":"Oncotarget"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13045-024-01623-9","article-title":"Global cancer statistics for adolescents and young adults: Population based study","volume":"17","author":"Li","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S2213-8587(22)00035-3","article-title":"The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020","volume":"10","author":"Pizzato","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"593479","DOI":"10.3389\/fonc.2021.593479","article-title":"Signal Pathway of Estrogen and Estrogen Receptor in the Development of Thyroid Cancer","volume":"11","author":"Liu","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Wang, H., Li, S., Shi, J., Feng, C., Wang, Y., and Zhang, F. (2023). Unbalanced bidirectional causal association between thyroid cancer and ER-positive breast cancer: Should we recommend screening for thyroid cancer in breast cancer patients?. BMC Genom., 24.","DOI":"10.1186\/s12864-023-09854-9"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/s41598-018-37648-7","article-title":"PES1 promotes the occurrence and development of papillary thyroid cancer by upregulating the ER\u03b1\/ER\u03b2 protein ratio","volume":"9","author":"Qiu","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"e21516","DOI":"10.1096\/fj.202001467R","article-title":"Methylation of ER\u03b2 5\u2032-untranslated region attenuates its inhibitory effect on ER\u03b1 gene transcription and promotes the initiation and progression of papillary thyroid cancer","volume":"35","author":"Xu","year":"2021","journal-title":"FASEB J."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.surg.2017.04.031","article-title":"Estrogen receptor subtype expression and regulation is altered in papillary thyroid cancer after menopause","volume":"163","author":"Rubio","year":"2018","journal-title":"Surgery"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"941568","DOI":"10.1155\/2013\/941568","article-title":"Estrogen Induces Metastatic Potential of Papillary Thyroid Cancer Cells through Estrogen Receptor \u03b1 and \u03b2","volume":"2013","author":"Dong","year":"2013","journal-title":"Int. J. Endocrinol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"117693","DOI":"10.1016\/j.lfs.2020.117693","article-title":"ETV5 overexpression contributes to tumor growth and progression of thyroid cancer through PIK3CA","volume":"253","author":"Meng","year":"2020","journal-title":"Life Sci."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Chou, C.K., Chi, S.Y., Hung, Y.Y., Yang, Y.C., Fu, H.C., Wang, J.H., Chen, C.C., and Kang, H.Y. (2022). Decreased Expression of Estrogen Receptors Is Associated with Tumorigenesis in Papillary Thyroid Carcinoma. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031015"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.4143\/crt.2020.1201","article-title":"Expression of Estrogen and Progesterone Receptors in Papillary Thyroid Carcinoma in Korea","volume":"53","author":"Ahn","year":"2021","journal-title":"Cancer Res. Treat."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"117112","DOI":"10.1016\/j.lfs.2019.117112","article-title":"GPER1 in the thyroid: A systematic review","volume":"241","author":"Manfroi","year":"2020","journal-title":"Life Sci."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"111397","DOI":"10.1016\/j.mce.2021.111397","article-title":"The gene expression of GPER1 is low in fresh samples of papillary thyroid carcinoma (PTC), and in silico analysis","volume":"535","author":"Bertoni","year":"2021","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3389\/fendo.2020.00082","article-title":"New Therapies for Advanced Thyroid Cancer","volume":"11","author":"Laha","year":"2020","journal-title":"Front. Endocrinol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"12478","DOI":"10.1038\/s41598-024-63155-z","article-title":"Risk of second primary thyroid cancer in cancer survivors","volume":"14","author":"Yuan","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Forma, A., K\u0142odnicka, K., Paj\u0105k, W., Flieger, J., Teresi\u0144ska, B., Januszewski, J., and Baj, J. (2025). Thyroid Cancer: Epidemiology, Classification, Risk Factors, Diagnostic and Prognostic Markers, and Current Treatment Strategies. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26115173"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"114229","DOI":"10.1016\/j.yexcr.2024.114229","article-title":"Leptin and insulin synergize with PIK3CA mutation to enhance PD-L1 mediated immunosuppression in thyroid cancer","volume":"442","author":"Wu","year":"2024","journal-title":"Exp. Cell Res."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"607909","DOI":"10.3389\/fonc.2020.607909","article-title":"Sexual Dimorphism in Colon Cancer","volume":"10","author":"Abancens","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_136","first-page":"233","article-title":"Colorectal cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1187259","DOI":"10.3389\/fendo.2023.1187259","article-title":"Profiling estrogen, progesterone, and androgen receptors in colorectal cancer in relation to gender, menopausal status, clinical stage, and tumour sidedness","volume":"14","author":"Refaat","year":"2023","journal-title":"Front. Endocrinol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1007\/s11033-020-05414-6","article-title":"Targeting estrogen receptors in colorectal cancer","volume":"47","author":"Maingi","year":"2020","journal-title":"Mol. Biol. Rep."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.3390\/curroncol28060361","article-title":"Estrogen Receptors in Colorectal Cancer: Facts, Novelties and Perspectives","volume":"28","author":"Ditonno","year":"2021","journal-title":"Curr. Oncol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"739620","DOI":"10.3389\/fmed.2022.739620","article-title":"Combined Estrogen Alpha and Beta Receptor Expression Has a Prognostic Significance for Colorectal Cancer Patients","volume":"9","author":"Topi","year":"2022","journal-title":"Front. Med."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s12964-024-01582-1","article-title":"High Oestrogen receptor alpha expression correlates with adverse prognosis and promotes metastasis in colorectal cancer","volume":"22","author":"Topi","year":"2024","journal-title":"Cell Commun. Signal."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.canlet.2020.06.021","article-title":"Intestinal estrogen receptor beta suppresses colon inflammation and tumorigenesis in both sexes","volume":"492","author":"Hases","year":"2020","journal-title":"Cancer Lett."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"650625","DOI":"10.3389\/fendo.2021.650625","article-title":"Estrogen Receptor Beta Influences the Inflammatory p65 Cistrome in Colon Cancer Cells","volume":"12","author":"Indukuri","year":"2021","journal-title":"Front. Endocrinol."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Bo\u017eovi\u0107, A., Mandu\u0161i\u0107, V., Todorovi\u0107, L., and Krajnovi\u0107, M. (2021). Estrogen Receptor Beta: The Promising Biomarker and Potential Target in Metastases. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22041656"},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Lu, L., Zhang, Q., Shen, X., Zhen, P., Marin, A., Garcia-Milian, R., Roper, J., Khan, S.A., and Johnson, C.H. (2023). Asparagine synthetase and G-protein coupled estrogen receptor are critical responders to nutrient supply in KRAS mutant colorectal cancer. bioRxiv.","DOI":"10.1101\/2023.05.05.539577"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.2147\/OTT.S291896","article-title":"Role of G Protein-Coupled Estrogen Receptor in Digestive System Carcinomas: A Minireview","volume":"14","author":"Qiu","year":"2021","journal-title":"OncoTargets Ther."},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Abancens, M., Harvey, B.J., and McBryan, J. (2022). GPER Agonist G1 Prevents Wnt-Induced JUN Upregulation in HT29 Colorectal Cancer Cells. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232012581"},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Ionescu, V.A., Gheorghe, G., Bacalbasa, N., Chiotoroiu, A.L., and Diaconu, C. (2023). Colorectal Cancer: From Risk Factors to Oncogenesis. Medicina, 59.","DOI":"10.20944\/preprints202308.1837.v1"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.giec.2021.12.008","article-title":"Risk Factors for Colorectal Polyps and Cancer","volume":"32","author":"Sninsky","year":"2022","journal-title":"Gastrointest. Endosc. Clin. N. Am."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"15065","DOI":"10.1038\/nrdp.2015.65","article-title":"Colorectal cancer","volume":"1","author":"Kuipers","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_151","unstructured":"(2025, September 22). Hormone Therapy for Brest Cancer, Available online: https:\/\/www.cancer.gov\/types\/breast\/breast-hormone-therapy-fact-sheet."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"105057","DOI":"10.1016\/j.esmoop.2025.105057","article-title":"Extended adjuvant endocrine therapy in early breast cancer: Finding the individual balance","volume":"10","author":"Arecco","year":"2025","journal-title":"ESMO Open"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"291","DOI":"10.31128\/AJGP-11-23-7028","article-title":"Evolution of hormonal therapy for prostate cancer","volume":"53","author":"Homewood","year":"2024","journal-title":"Aust. J. Gen. Pract."},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Mitra, S., Lami, M.S., Ghosh, A., Das, R., Tallei, T.E., Fatimawali Islam, F., Dhama, K., Begum, M.Y., Aldahish, A., and Chidambaram, K. (2022). Hormonal Therapy for Gynecological Cancers: How Far Has Science Progressed toward Clinical Applications?. Cancers, 14.","DOI":"10.3390\/cancers14030759"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/ncpendmet0020","article-title":"Thyroid-hormone therapy and thyroid cancer: A reassessment","volume":"1","author":"Biondi","year":"2005","journal-title":"Nat. Clin. Pract. Endocrinol. Metab."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/s41392-025-02270-3","article-title":"Nuclear receptors in health and disease: Signaling pathways, biological functions and pharmaceutical interventions","volume":"10","author":"Jin","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.maturitas.2010.05.009","article-title":"SERMs: Progress and future perspectives","volume":"67","author":"Pickar","year":"2010","journal-title":"Maturitas"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.maturitas.2014.10.010","article-title":"Selective estrogen receptor modulators (SERMs): A review of clinical data","volume":"80","author":"Mirkin","year":"2015","journal-title":"Maturitas"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1097\/GME.0000000000001095","article-title":"Tissue selective estrogen complex (TSEC): A review","volume":"25","author":"Pickar","year":"2018","journal-title":"Menopause"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4331\/wjbc.v6.i3.231","article-title":"Current medical treatment of estrogen receptor-positive breast cancer","volume":"6","author":"Lumachi","year":"2015","journal-title":"World J. Biol. Chem."},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Zhao, L., Liu, Y., Zhang, J., Zheng, L., and Zheng, M. (2024). Adverse Event Profiles of the Third-Generation Aromatase Inhibitors: Analysis of Spontaneous Reports Submitted to FAERS. Biomedicines, 12.","DOI":"10.3390\/biomedicines12081708"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0140-6736(12)61963-1","article-title":"Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial","volume":"381","author":"Davies","year":"2013","journal-title":"Lancet"},{"key":"ref_163","unstructured":"(2025, September 22). Available online: https:\/\/www.guidetopharmacology.org\/GRAC\/LigandDisplayForward?ligandId=2817."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"5624","DOI":"10.1111\/bph.12864","article-title":"Simulation with cells in vitro of tamoxifen treatment in premenopausal breast cancer patients with different CYP2D6 genotypes","volume":"171","author":"Maximov","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"ref_165","first-page":"205","article-title":"Persistent synergistic antiproliferative and apoptosis induction effects of PGV-1 and tamoxifen or 4-hydroxytamoxifen on ER-positive breast cancer cells","volume":"15","author":"Rahmawati","year":"2025","journal-title":"J. Appl. Pharm. Sci."},{"key":"ref_166","first-page":"1437","article-title":"Selective estrogen receptor modulators: Tissue specificity and clinical utility","volume":"9","author":"Martinkovich","year":"2014","journal-title":"Clin. Interv. Aging"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S1548-5315(12)70048-7","article-title":"Understanding the estrogen receptor signaling pathway: Focus on current endocrine agents for breast cancer in postmenopausal women","volume":"8","author":"Brufsky","year":"2011","journal-title":"Community Oncol."},{"key":"ref_168","first-page":"169","article-title":"Nuclear receptor corepressor complexes in cancer: Mechanism, function and regulation","volume":"2","author":"Wong","year":"2014","journal-title":"Am. J. Clin. Exp. Urol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1126\/science.1068537","article-title":"Molecular determinants for the tissue specificity of SERMs","volume":"295","author":"Shang","year":"2002","journal-title":"Science"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"135","DOI":"10.6026\/97320630012135","article-title":"Molecular mechanisms and mode of tamoxifen resistance in breast cancer","volume":"12","author":"Ali","year":"2016","journal-title":"Bioinformation"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1210\/me.2016-1072","article-title":"Minireview: The Link Between ER\u03b1 Corepressors and Histone Deacetylases in Tamoxifen Resistance in Breast Cancer","volume":"30","author":"Basik","year":"2016","journal-title":"Mol. Endocrinol."},{"key":"ref_172","first-page":"e1806","article-title":"Tamoxifen use and risk of endometrial cancer in breast cancer patients: A systematic review and dose-response meta-analysis","volume":"6","author":"Ghanavati","year":"2023","journal-title":"Cancer Rep."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"393","DOI":"10.5306\/wjco.v5.i3.393","article-title":"Toremifene in the treatment of breast cancer","volume":"5","author":"Mustonen","year":"2014","journal-title":"World J. Clin. Oncol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/0006-2952(94)90319-0","article-title":"Involvement of cytochrome P450 3A enzyme family in the major metabolic pathways of toremifene in human liver microsomes","volume":"47","author":"Berthou","year":"1994","journal-title":"Biochem. Pharmacol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1002\/ijc.27794","article-title":"Role and pharmacologic significance of cytochrome P-450 2D6 in oxidative metabolism of toremifene and tamoxifen","volume":"132","author":"Kim","year":"2013","journal-title":"Int. J. Cancer"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2165\/00003495-199754010-00014","article-title":"L Toremifene: A review of its pharmacological properties and clinical efficacy in the management of advanced breast cancer","volume":"54","author":"Wiseman","year":"1997","journal-title":"Drugs"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/BF00689269","article-title":"Biochemical and pharmacological effects of toremifene metabolites","volume":"27","author":"Kangas","year":"1990","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1080\/17512433.2016.1231575","article-title":"Raloxifene hydrochloride for breast cancer risk reduction in postmenopausal women","volume":"9","author":"Provinciali","year":"2016","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1158\/1940-6207.CAPR-12-0448","article-title":"Characterization of raloxifene glucuronidation: Potential role of UGT1A8 genotype on raloxifene metabolism in vivo","volume":"6","author":"Sun","year":"2013","journal-title":"Cancer Prev. Res."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0960-0760(97)00008-3","article-title":"Evaluation of the major metabolites of raloxifene as modulators of tissue selectivity","volume":"61","author":"Dodge","year":"1997","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3181\/00379727-217-44204","article-title":"Selective estrogen receptor modulators: An alternative to hormone replacement therapy","volume":"217","author":"Bryant","year":"1998","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1093\/ajhp\/57.18.1669","article-title":"Raloxifene hydrochloride","volume":"57","author":"Snyder","year":"2000","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2174\/1874325000903010014","article-title":"Raloxifene: Mechanism of action, effects on bone tissue, and applicability in clinical traumatology practice","volume":"3","author":"Rey","year":"2009","journal-title":"Open Orthop. J."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1126\/science.273.5279.1222","article-title":"Identification of an estrogen response element activated by metabolites of 17beta-estradiol and raloxifene","volume":"273","author":"Yang","year":"1996","journal-title":"Science"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"549","DOI":"10.3346\/jkms.2001.16.5.549","article-title":"Identification of a mutation in the human raloxifene response element of the transforming growth factor-beta 3 gene","volume":"16","author":"Han","year":"2001","journal-title":"J. Korean Med. Sci."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"807","DOI":"10.2165\/00003495-200161060-00013","article-title":"Fulvestrant","volume":"61","author":"Curran","year":"2001","journal-title":"Drugs"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1564642","DOI":"10.3389\/or.2025.1564642","article-title":"Treating ER-positive breast cancer: A review of the current FDA-approved SERMs and SERDs and their mechanisms of action","volume":"19","author":"Kim","year":"2025","journal-title":"Oncol. Rev."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1038\/sj.bjc.6601630","article-title":"Fulvestrant: Pharmacokinetics and pharmacology","volume":"90","author":"Robertson","year":"2004","journal-title":"Br. J. Cancer"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.3816\/CBC.2005.s.008","article-title":"The history and mechanism of action of fulvestrant","volume":"6","author":"Carlson","year":"2005","journal-title":"Clin. Breast Cancer."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1749-6632.1995.tb31376.x","article-title":"Responses to pure antiestrogens (ICI 164384, ICI 182780) in estrogen-sensitive and -resistant experimental and clinical breast cancer","volume":"761","author":"Nicholson","year":"1995","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"9607","DOI":"10.1074\/jbc.M510809200","article-title":"Fulvestrant (ICI 182,780)-dependent interacting proteins mediate immobilization and degradation of estrogen receptor-alpha","volume":"281","author":"Long","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jsbmb.2011.02.001","article-title":"Aromatase, aromatase inhibitors, and breast cancer","volume":"125","author":"Chumsri","year":"2011","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1196\/annals.1386.022","article-title":"Aromatase inhibitors: Structural features and biochemical characterization","volume":"1089","author":"Hong","year":"2006","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"106729","DOI":"10.1016\/j.jsbmb.2025.106729","article-title":"The current landscape of aromatase inhibitors for the treatment of estrogen receptor-positive breast carcinoma","volume":"250","author":"Bhutani","year":"2025","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"ref_195","first-page":"234","article-title":"Unlocking the Potential of Aromatase Inhibitors: Recent Advances in Drug Design, Synthesis, Docking Activity, and in Vitro Bioactivity Evaluations","volume":"3","year":"2023","journal-title":"Synth. Sinter."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000350774","article-title":"A Brief Overview of the WHO Classification of Breast Tumors, 4th Edition, Focusing on Issues and Updates from the 3rd Edition","volume":"8","author":"Sinn","year":"2013","journal-title":"Breast Care"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40164-022-00363-1","article-title":"Breast cancer heterogeneity and its implication in personalized precision therapy","volume":"12","author":"Guo","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_198","doi-asserted-by":"crossref","unstructured":"Testa, U., Castelli, G., and Pelosi, E. (2020). Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments. Med. Sci., 8.","DOI":"10.3390\/medsci8010018"},{"key":"ref_199","doi-asserted-by":"crossref","unstructured":"Ferreira Almeida, C., Correia-da-Silva, G., Teixeira, N., and Amaral, C. (2024). Influence of tumor microenvironment on the different breast cancer subtypes and applied therapies. Biochem. Pharmacol., 223.","DOI":"10.1016\/j.bcp.2024.116178"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ccr.2012.02.022","article-title":"Accessories to the crime: Functions of cells recruited to the tumor microenvironment","volume":"21","author":"Hanahan","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s10555-024-10166-x","article-title":"The impact of tumor microenvironment: Unraveling the role of physical cues in breast cancer progression","volume":"43","author":"Akinpelu","year":"2024","journal-title":"Cancer Metastasis Rev."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"104683","DOI":"10.1016\/j.phrs.2020.104683","article-title":"Tumor microenvironment: Challenges and opportunities in targeting metastasis of triple negative breast cancer","volume":"153","author":"Deepak","year":"2020","journal-title":"Pharmacol. Res."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41392-020-00261-0","article-title":"Exosomes: Key players in cancer and potential therapeutic strategy","volume":"5","author":"Dai","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"1901779","DOI":"10.1002\/advs.201901779","article-title":"Extracellular Vesicles in Cancer Immune Microenvironment and Cancer Immunotherapy","volume":"6","author":"Xie","year":"2019","journal-title":"Adv. Sci."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12935-020-01659-0","article-title":"Exosomes from tamoxifen-resistant breast cancer cells transmit drug resistance partly by delivering miR-9-5p","volume":"21","author":"Liu","year":"2021","journal-title":"Cancer Cell Int."},{"key":"ref_206","doi-asserted-by":"crossref","unstructured":"La Camera, G., Gelsomino, L., Caruso, A., Panza, S., Barone, I., Bonofiglio, D., And\u00f2, S., Giordano, C., and Catalano, S. (2021). The Emerging Role of Extracellular Vesicles in Endocrine Resistant Breast Cancer. Cancers, 13.","DOI":"10.3390\/cancers13051160"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41523-023-00523-4","article-title":"An emerging generation of endocrine therapies in breast cancer: A clinical perspective","volume":"9","author":"Patel","year":"2023","journal-title":"npj Breast Cancer"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ccell.2020.03.009","article-title":"Overcoming Endocrine Resistance in Breast Cancer","volume":"37","author":"Hanker","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_210","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG) (2025). Extending the duration of endocrine treatment for early breast cancer: Patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22,031 postmenopausal women already treated with at least 5 years of endocrine therapy. Lancet, 406, 603\u2013614."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"100012","DOI":"10.1016\/j.aspetd.2025.100012","article-title":"Integrative Strategies in Breast Cancer Therapy: Conventional Approaches, Emerging Advances, and Future Challenges","volume":"1","author":"Eapen","year":"2025","journal-title":"ASPET Discov."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1200\/JCO.2000.18.20.3471","article-title":"HER-2\/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer","volume":"18","author":"Berry","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/sj.bjc.6690112","article-title":"Altered expression of the IGF-1 receptor in a tamoxifen-resistant human breast cancer cell line","volume":"79","author":"Parisot","year":"1999","journal-title":"Br. J. Cancer"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.2174\/0929867322666150416095744","article-title":"Factors Promoting Tamoxifen Resistance in Breast Cancer via Stimulating Breast Cancer Stem Cell Expansion","volume":"22","author":"Ojo","year":"2015","journal-title":"Curr. Med. Chem."},{"key":"ref_215","first-page":"2435","article-title":"HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells","volume":"10","author":"Pietras","year":"1995","journal-title":"Oncogene"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.maturitas.2006.06.003","article-title":"Role of estrogen receptor alpha transcriptional coregulators in tamoxifen resistance in breast cancer","volume":"54","author":"Girault","year":"2006","journal-title":"Maturitas"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.prp.2015.01.004","article-title":"Tamoxifen resistance: From cell culture experiments towards novel biomarkers","volume":"211","author":"Nass","year":"2015","journal-title":"Pathol. Res. Pract."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S1569-254X(98)80004-6","article-title":"Growth factor signal transduction and hormone independence in breast cancer","volume":"2","author":"Miller","year":"1999","journal-title":"Adv. Oncobiol."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jsbmb.2005.07.002","article-title":"Co-expression of steroid hormone receptors (estrogen receptor alpha and\/or progesterone receptors) and Her2\/neu (c-erbB-2) in breast cancer: Clinical outcome following tamoxifen-based adjuvant therapy","volume":"98","author":"Gago","year":"2006","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1210\/er.2006-0045","article-title":"Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: Molecular mechanism and clinical implications for endocrine therapy resistance","volume":"29","author":"Arpino","year":"2008","journal-title":"Endocr. Rev."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.1158\/1078-0432.CCR-07-1373","article-title":"Membrane-associated estrogen receptor signaling pathways in human cancers","volume":"13","author":"Pietras","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_222","first-page":"7025","article-title":"Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells","volume":"61","author":"Yang","year":"2001","journal-title":"Cancer Res."},{"key":"ref_223","first-page":"4026","article-title":"A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions","volume":"60","author":"Fuqua","year":"2000","journal-title":"Cancer Res."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/sj.tpj.6500201","article-title":"Multiple mechanisms of estrogen receptor gene repression contribute to ER-negative breast cancer","volume":"3","author":"Parl","year":"2003","journal-title":"Pharmacogenom. J."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nrendo.2011.122","article-title":"The G-protein-coupled estrogen receptor GPER in health and disease","volume":"7","author":"Prossnitz","year":"2011","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1210\/mend.14.10.0532","article-title":"Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF","volume":"14","author":"Filardo","year":"2000","journal-title":"Mol. Endocrinol."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1126\/science.1106943","article-title":"A transmembrane intracellular estrogen receptor mediates rapid cell signaling","volume":"307","author":"Revankar","year":"2005","journal-title":"Science"},{"key":"ref_228","first-page":"433","article-title":"Androgens and androgen receptor: Do they play a role in breast cancer?","volume":"6","year":"2000","journal-title":"Med. Sci. Monit."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10549-009-0436-8","article-title":"Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells","volume":"121","author":"Thirugnansampanthan","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10549-015-3609-7","article-title":"Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ER\u03b1-positive breast cancer","volume":"154","author":"Ciupek","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1615\/CritRevEukarGeneExpr.v5.i2.10","article-title":"Androgen receptor: An overview","volume":"5","author":"Chang","year":"1995","journal-title":"Crit. Rev. Eukaryot. Gene Expr."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"284036","DOI":"10.1155\/2013\/284036","article-title":"Sex hormone receptor repertoire in breast cancer","volume":"2013","author":"Higa","year":"2013","journal-title":"Int. J. Breast Cancer"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"T183","DOI":"10.1530\/ERC-14-0248","article-title":"Bringing androgens up a NOTCH in breast cancer","volume":"21","author":"Tarulli","year":"2014","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_234","doi-asserted-by":"crossref","unstructured":"Cuenca-L\u00f3pez, M.D., Montero, J.C., Morales, J.C., Prat, A., Pandiella, A., and Ocana, A. (2014). Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling. BMC Cancer., 14.","DOI":"10.1186\/1471-2407-14-302"},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1210\/me.2002-0070","article-title":"The roles of androgen receptors and androgen-binding proteins in nongenomic androgen actions","volume":"16","author":"Heinlein","year":"2002","journal-title":"Mol. Endocrinol."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/jmcb\/mjp052","article-title":"Context-dependent regulation of the GLI code in cancer by HEDGEHOG and non-HEDGEHOG signals","volume":"2","author":"Stecca","year":"2010","journal-title":"J. Mol. Cell Biol."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/0008-5472.CAN-10-2993","article-title":"TGF-beta promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical Hedgehog signaling","volume":"71","author":"Johnson","year":"2011","journal-title":"Cancer Res."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"5606","DOI":"10.1158\/0008-5472.CAN-11-1194","article-title":"TGF-\u03b2\/SMAD\/GLI2 signaling axis in cancer progression and metastasis","volume":"71","author":"Javelaud","year":"2011","journal-title":"Cancer Res."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"5048","DOI":"10.1158\/0008-5472.CAN-12-1248","article-title":"Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K\/AKT pathway","volume":"72","author":"Ramaswamy","year":"2012","journal-title":"Cancer Res."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/s41417-024-00747-x","article-title":"Recent progress of CDK4\/6 inhibitors\u2032 current practice in breast cancer","volume":"31","author":"Wang","year":"2024","journal-title":"Cancer Gene Ther."},{"key":"ref_241","doi-asserted-by":"crossref","unstructured":"Gallanis, G.T., Sharif, G.M., Schmidt, M.O., Friedland, B.N., Battina, R., Rahhal, R., Davis, J.E., Khan, I.S., Wellstein, A., and Riegel, A.T. (2023). Stromal Senescence following Treatment with the CDK4\/6 Inhibitor Palbociclib Alters the Lung Metastatic Niche and Increases Metastasis of Drug-Resistant Mammary Cancer Cells. Cancers, 15.","DOI":"10.3390\/cancers15061908"},{"key":"ref_242","doi-asserted-by":"crossref","unstructured":"Roberto, M., Astone, A., Botticelli, A., Carbognin, L., Cassano, A., D\u2019Auria, G., Fabbri, A., Fabi, A., Gamucci, T., and Krasniqi, E. (2021). CDK4\/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives. Cancers, 13.","DOI":"10.3390\/cancers13020332"},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor\u2013positive advanced breast cancer","volume":"380","author":"Ciruelos","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1158\/1078-0432.CCR-16-2339","article-title":"A Phase I\/Ib Study of Enzalutamide Alone and in Combination with Endocrine Therapies in Women with Advanced Breast Cancer","volume":"23","author":"Schwartzberg","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_245","doi-asserted-by":"crossref","unstructured":"Lu, Q., Xia, W., Lee, K., Zhang, J., Yuan, H., Yuan, Z., Shi, Y., Wang, S., and Xu, F. (2020). Bicalutamide plus Aromatase Inhibitor in Patients with Estrogen Receptor-Positive\/Androgen Receptor-Positive Advanced Breast Cancer. Oncologist, 25.","DOI":"10.1634\/theoncologist.2019-0564"},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"901152","DOI":"10.3389\/fonc.2022.901152","article-title":"Efficacy and Safety Profile of Histone Deacetylase Inhibitors for Metastatic Breast Cancer: A Meta-Analysis","volume":"12","author":"Wang","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_247","doi-asserted-by":"crossref","unstructured":"Wawruszak, A., Borkiewicz, L., Okon, E., Kukula-Koch, W., Afshan, S., and Halasa, M. (2021). Vorinostat (SAHA) and Breast Cancer: An Overview. Cancers, 13.","DOI":"10.3390\/cancers13184700"},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1158\/1078-0432.CCR-15-1718","article-title":"A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer","volume":"22","author":"Patnaik","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.ejca.2015.03.016","article-title":"Fulvestrant with or without selumetinib, a MEK 1\/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: A multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21\/08","volume":"51","author":"Zaman","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"ref_250","first-page":"5155","article-title":"Chemoresistance in breast cancer: PI3K\/Akt pathway inhibitors vs the current chemotherapy","volume":"11","author":"Kaboli","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1200\/JCO.20.03565","article-title":"Next-Generation Endocrine Therapies for Breast Cancer","volume":"39","author":"McDonnell","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ccell.2018.08.008","article-title":"The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers","volume":"34","author":"Razavi","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.annonc.2023.09.3104","article-title":"Lasofoxifene versus fulvestrant for ER+\/HER2- metastatic breast cancer with an ESR1 mutation: Results from the randomized, phase II ELAINE 1 trial","volume":"34","author":"Goetz","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1080\/14796694.2025.2481825","article-title":"ELAINE 3: Phase 3 study of lasofoxifene plus abemaciclib to treat ER+\/HER2-, ESR1-mutated, metastatic breast cancer","volume":"21","author":"Goetz","year":"2025","journal-title":"Future Oncol."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.coph.2010.09.007","article-title":"The molecular mechanisms underlying the pharmacological actions of ER modulators: Implications for new drug discovery in breast cancer","volume":"10","author":"McDonnell","year":"2010","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1530\/ERC-15-0287","article-title":"Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader","volume":"22","author":"Wardell","year":"2015","journal-title":"Endocr. Relat. Cancer."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00280-023-04550-7","article-title":"Pharmacology and pharmacokinetics of elacestrant","volume":"92","author":"Beumer","year":"2023","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"1002293","DOI":"10.37349\/etat.2025.1002293","article-title":"Elacestrant in hormone receptor-positive metastatic breast cancer: A post-hoc analysis","volume":"6","author":"Sarfraz","year":"2025","journal-title":"Explor. Target. Antitumor Ther."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"S370","DOI":"10.1016\/j.annonc.2024.08.312","article-title":"364P Elacestrant in combination with abemaciclib in patients (pts) with brain metastasis (mets) from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer: Preliminary data from ELECTRA, an open-label, multicenter, phase Ib\/II study","volume":"35","author":"Ciruelos","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1200\/JCO.2022.40.16_suppl.1032","article-title":"Serena-1: Updated analyses from a phase 1 study (parts C\/D) of the next-generation oral SERD camizestrant (AZD9833) in combination with palbociclib, in women with ER-positive, HER2-negative advanced breast cancer","volume":"40","author":"Oliveira","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1158\/1538-7445.AM2021-1236","article-title":"Preclinical characterization of LY3484356, a novel, potent and orally bioavailable selective estrogen receptor degrader (SERD)","volume":"81","author":"Bhagwat","year":"2021","journal-title":"Cancer Res."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nchembio.1858","article-title":"Catalytic in vivo protein knockdown by small-molecule PROTACs","volume":"11","author":"Bondeson","year":"2015","journal-title":"Nat. Chem. Biol."},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"112689","DOI":"10.1016\/j.ejmech.2020.112689","article-title":"Targeting estrogen receptor \u03b1 for degradation with PROTACs: A promising approach to overcome endocrine resistance","volume":"206","author":"Lin","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"P5-04-18","DOI":"10.1158\/1538-7445.SABCS18-P5-04-18","article-title":"Abstract P5-04-18: ARV-471, an oral estrogen receptor PROTAC degrader for breast cancer","volume":"79","author":"Flanagan","year":"2019","journal-title":"Cancer Res."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"P5-05-02","DOI":"10.1158\/1538-7445.SABCS19-P5-05-02","article-title":"Abstract P5-05-02: Preclinical development of OP-1250, an oral complete estrogen receptor antagonist (CERAN) that shrinks ER-positive breast tumors in xenograft models","volume":"80","author":"Sun","year":"2020","journal-title":"Cancer Res."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1158\/1535-7163.MCT-23-0351","article-title":"Palazestrant (OP-1250), A Complete Estrogen Receptor Antagonist, Inhibits Wild-type and Mutant ER-positive Breast Cancer Models as Monotherapy and in Combination","volume":"23","author":"Parisian","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1158\/2159-8290.CD-17-1229","article-title":"Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ER\u03b1WT and ER\u03b1MUT Breast Cancer","volume":"8","author":"Puyang","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"200941","DOI":"10.1016\/j.omton.2025.200941","article-title":"miRNA-dependent resistance mechanisms to anti-hormonal therapies in estrogen receptor-positive breast cancer patients","volume":"33","author":"Mourits","year":"2025","journal-title":"Mol. Ther. Oncol."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4048\/jbc.2020.23.e10","article-title":"The Role of Long Noncoding RNAs in Antiestrogen Resistance in Breast Cancer: An Overview and Update","volume":"23","author":"Huang","year":"2020","journal-title":"J. Breast Cancer"},{"key":"ref_270","first-page":"30","article-title":"Rola leczenia hormonalnego u pacjent\u00f3w z zaawansowan\u0105 chorob\u0105 nowotworow\u0105","volume":"9","author":"Leppert","year":"2015","journal-title":"Med. Paliatywna Prakt."},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ctrv.2017.02.005","article-title":"Ovarian ablation for premenopausal breast cancer: A review of treatment considerations and the impact of premature menopause","volume":"55","author":"Nourmoussavi","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"ref_272","doi-asserted-by":"crossref","unstructured":"Castell\u00f3n, E.A., Indo, S., and Contreras, H.R. (2022). Cancer Stemness\/Epithelial-Mesenchymal Transition Axis Influences Metastasis and Castration Resistance in Prostate Cancer: Potential Therapeutic Target. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232314917"},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s12253-018-00569-x","article-title":"Hormone Replacement Therapy in Cancer Survivors-Review of the Literature","volume":"26","author":"Deli","year":"2020","journal-title":"Pathol. Oncol. Res."},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"101577","DOI":"10.1016\/j.beem.2021.101577","article-title":"Menopausal hormone therapy and breast cancer risk","volume":"35","author":"Rozenberg","year":"2021","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/humupd\/dmac038","article-title":"Contraceptives and cancer risks in BRCA1\/2 pathogenic variant carriers: A systematic review and meta-analysis","volume":"29","author":"IntHout","year":"2023","journal-title":"Hum. Reprod. Update"},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s42000-023-00519-6","article-title":"Contraception as chemoprevention of ovarian cancer in BRCA1 and BRCA2 women","volume":"23","author":"Loizzi","year":"2024","journal-title":"Hormones"},{"key":"ref_277","doi-asserted-by":"crossref","unstructured":"Wang, X., Ha, D., Yoshitake, R., Chan, Y.S., Sadava, D., and Chen, S. (2021). Exploring the Biological Activity and Mechanism of Xenoestrogens and Phytoestrogens in Cancers: Emerging Methods and Concepts. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22168798"},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"113037","DOI":"10.1016\/j.ejmech.2020.113037","article-title":"Engagement of phytoestrogens in breast cancer suppression: Structural classification and mechanistic approach","volume":"213","author":"Tanwar","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"107985","DOI":"10.1016\/j.envint.2023.107985","article-title":"Estrogens in plants and emerging risks to human health","volume":"178","author":"Adeel","year":"2023","journal-title":"Environ. Int."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/13\/11\/2620\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:23:13Z","timestamp":1761628993000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/13\/11\/2620"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,26]]},"references-count":279,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["biomedicines13112620"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines13112620","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,26]]}}}